Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | MAP2 | P11137 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20569068 | 0.90 | PDE3B (0.35) | PTGS2MCL1SCN9AKDM4EALDH1A1 | |
| SCHEMBL23327335 | 0.86 | STK10 (0.34) | PPARGSCN9AFABP4 | |
| SCHEMBL23348208 | 0.85 | BRAF (0.38) | BRAFPTGS2SCN9AMEN1KMT2A | |
| SCHEMBL30794689 | 0.80 | KDM4E (0.53) | MAP2MCL1GPR35KDM4EMEN1 | |
| SCHEMBL20569058 | 0.78 | MAP2 (0.46) | MAP2PPARGGRIN1GPR35KDM4E | |
| SCHEMBL3345001 | 0.78 | KDM4E (0.49) | MAP2PPARGMCL1GPR35KDM4E | |
| SCHEMBL20568466 | 0.76 | STK10 (0.34) | MCL1SCN9AHTT | |
| SCHEMBL29750710 | 0.76 | SCN9A (0.35) | BRAFPTGS2SCN9A | |
| SCHEMBL23327628 | 0.74 | NEK1 (0.38) | MAP2SCN9AGPR35KDM4EMEN1 | |
| SCHEMBL20568345 | 0.74 | NEK1 (0.39) | MAP2GRIN1GPR35GPR17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11413272-B2 | Inhibitors of metallo-beta-lactamases | OXFORD UNIVERSITY INNOVATION LIMITED | 2022-08-16 | — | — | US | disclosed |
| EP-3630728-B1 | INHIBITORS OF METALLO-BETA-LACTAMASES | UNIV OXFORD INNOVATION LTD (GB) | 2022-07-27 | — | — | EP | disclosed |
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3630728-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | Oxford University Innovation Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215799-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11413272-B2 | Inhibitors of metallo-beta-lactamases | MGAM, GAA, ALPI | BRAF 3848/4885MAP2 2165/4885PPARG 3605/4885 |
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, GAA, ALPI | BRAF 3848/4885MAP2 2165/4885PPARG 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.